A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aridis Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

1. Colonized with Staphylococcus aureus;

2. Expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia.

Exclusion Criteria:

1. Staphylococcal disease at randomisation;

2. Lung injury score consistent with pneumonia;

3. Chronic tracheostomy patients;

4. The study subject is moribund

5. Receipt of anti- S. aureus systemic antibiotics

6. Active pulmonary disease